🔗 Share this article

The initial novel therapies for gonorrhoea in decades are being described as a "major milestone" in the fight against increasingly resistant strains of the infection, according to scientists.

An International Challenge

The sexually transmitted infection are escalating globally, with figures suggesting more than 82 million infections per year. Especially elevated rates are observed in the African continent and nations within the WHO's Western Pacific region, which spans from China and Mongolia to New Zealand. In England, cases have reached a historical peak, while figures across Europe in 2023 were significantly elevated compared to those in 2014.

“The authorization of fresh medications for gonorrhoea is an significant and necessary advancement in the context of increasing worldwide cases, the spread of superbugs and the highly restricted treatment choices at this time.”

Public health authorities are increasingly worried about the increase in treatment-resistant strains. The WHO has classified it as a "high-priority threat". A tracking program showed that the effectiveness of standard treatments like ceftriaxone and cefixime increased dramatically between 2022 and 2024.

Recent Drugs Gain Authorization

One new antibiotic, marketed under the name Nuzolvence, was approved by the American regulatory agency in December for combating gonorrhoea. This infection can lead to significant complications, including infertility. Scientists anticipate that focused deployment of this new drug will help delay the development of resistance.

Gepotidacin, originating from the pharmaceutical company GSK, also received approval in concurrent days. This treatment, which is employed against urinary tract infections, was shown in trials to be able to combat drug-resistant strains of the gonorrhoea bacteria.

A Novel Partnership

Zoliflodacin stemmed from a new, not-for-profit approach for antibiotic development. The charitable organization GARDP collaborated with the pharmaceutical company its industry partner to bring it to fruition.

“This approval represents a major breakthrough in the treatment of multidrug-resistant gonorrhoea, which up to this point has been evolving faster than medical innovation.”

Testing Data and Worldwide Availability

As per findings detailed in a prominent scientific publication, the new drug cured the vast majority of cases of the STI. This establishes an comparable level with the typical regimen, which involves two antibiotics. The trial involved over 900 participants from several countries including the United States, Thailand, South Africa, and European nations.

Through the arrangement of its unique model, the non-profit has the authority to make available and distribute the drug in numerous low-income and middle-income countries.

Doctors directly involved have voiced hope. Having a single-dose, oral treatment of this kind is seen as a "game-changer" for public health efforts. This is deemed vital to reduce the burden of the disease for individuals and to halt the transmission of highly drug-resistant gonorrhoea globally.